Healing minds.
Transforming lives.

BlackThorn Therapeutics is dedicated to improving the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments.
Who we are

About

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company that uses a novel and robust approach (INFORM™) to link behavioral deficits with brain physiology to discover and develop targeted treatments for neurobehavioral disorders. We envision a future where patients with neurobehavioral disorders are quickly recognized, accurately diagnosed and effectively treated.

Our Approach

Science

BlackThorn’s INFORM™ (Integrated Functional Objective Research Measures) approach creates an understanding of the core underlying pathophysiology of neurobehavioral disorders and generates objective neuromarkers.

INFORM enables BlackThorn to identify promising drug targets, select patients based on a physiologic link to those targets and objectively measure behavioral endpoints. The result is smaller trials, targeted to the right patients and with a higher probability of success.

Research & Development

Pipeline

BlackThorn is building a sustainable pipeline of treatments in major areas of unmet need. Our portfolio of first- and best-in-class small molecules modulates targets that are expressed in key brain regions of interest and that regulate behaviors integral to multiple disorders.

Program Discovery Preclinical Phase 1 Phase 2 Phase 3 NDA
BTRX-246040
BTRX-335140
BTRX Program 3
BTRX Program 4
Program Phase
BTRX-246040 2
BTRX-335140 1
BTRX Program 3 Preclinical
BTRX Program 4 Discovery
Our People

Team

BlackThorn is led by a team of seasoned professionals with deep expertise in neurobehavioral disorders and drug discovery and development.

President and Chief Executive Officer

Charles Gregory Vontz

Chief Scientific Officer

Bill Martin, Ph.D.

Chief Medical Officer

Annette Madrid, M.D.

Director

Asish K. Xavier, Ph.D.

View ›

Chairman

Mark Corrigan, M.D.

View ›

Director

Kristina Burow

View ›

Director

Matthew Fust

View ›

Director

George S. Golumbeski, Ph.D.

View ›

Director

John MacPhee

View ›

President and Chief Executive Officer

Charles Gregory Vontz

View ›

SAB Co-Chair

Matthew W. State M.D., Ph.D.

View ›

SAB Co-Chair

Steven E. Hyman, M.D.

View ›

Chemistry Advisor

Jin-Quan Yu, Ph.D.

View ›

Senior Advisor

Thomas O. Daniel, M.D.

View ›

SAB Member

Bernardo Sabatini, M.D., Ph.D.

View ›

SAB Member

John H. Krystal, M.D.

View ›

SAB Member

Alan Anticevic, Ph.D.

View ›

Scientific Founder

Hugh Rosen, M.D., Ph.D.

View ›

Scientific Founder

Edward Roberts, Ph.D.

View ›

Founder

Alex Tkachenko, Ph.D.

View ›

If you are interested in joining the BlackThorn team, please visit our careers page to learn about current job opportunities.

Our Newsroom

Recent News & Announcements

Aug 6, 2018
BlackThorn Therapeutics Announces Exclusive Licensing Agreement and Extension of Key Collaboration with Yale University
Jun 12, 2018
BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors
Jun 6, 2018
BlackThorn Therapeutics Initiates Phase 1 Study of BTRX-335140, an Investigational Kappa Opioid Receptor (KOR) Antagonist
Dec 7, 2017
BlackThorn Therapeutics Presents Preclinical and Clinical Data from Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting
Sep 26, 2017
BlackThorn Selected as a Fierce15 2017 Winner
1 2 3 4
Get In Touch

Contact Us

Address
Email
San Francisco

780 Brannan Street
San Francisco, CA 94103

Stay Connected

Get BlackThorn News & Updates